JARID2 is a nuclear protein that serves as a critical accessory subunit of the Polycomb Repressive Complex 2 (PRC2), which catalyzes histone H3K27 trimethylation (H3K27me3) for transcriptional repression 1. Structurally, JARID2 mimics methylated histone H3 tails and stimulates PRC2 enzymatic activity while simultaneously promoting PRC2 recruitment to target chr6 23. This dual function as a "molecular rheostat" finely calibrates PRC2 activity at developmental genes. JARID2 is essential for embryonic development, including cardiac, hepatic, and hematopoietic differentiation, as well as neural tube fusion 1. In cancer contexts, JARID2 is upregulated and promotes tumorigenesis through multiple mechanisms: it cooperates with the NuRD complex to repress tumor suppressors like BRCA2 and RB1 in breast cancer 4, competes with PALI1 for PRC2 binding in prostate cancer 5, and participates in mechanotransduction-driven fibrosis 6. Loss-of-function JARID2 variants cause a neurodevelopmental syndrome characterized by developmental delay, intellectual disability, hypotonia, and dysmorphic features, with a distinct DNA methylation signature identifying affected individuals 7. Thus, JARID2 functions as both a developmental regulator and oncogenic factor with therapeutic implications.